Publication Name	World Journal of Clinical Cases
Manuscript ID	65277
Country	Taiwan

Received	2021-03-03 04:35
Peer-Review Started	2021-03-03 04:42
To Make the First Decision
Return for Revision	2021-04-20 15:41
Revised	2021-04-22 16:55
Second Decision	2021-08-09 02:24
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-08-09 03:33
Articles in Press	2021-08-09 03:33
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-08-20 20:55
Typeset the Manuscript	2021-09-13 00:45
Publish the Manuscript Online	2021-09-16 08:48

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Impact of COVID-19 on liver
Manuscript Source	Invited Manuscript
All Author List	Yu-Jang Su, Chen-Wang Chang, Ming-Jen Chen and Yen-Chun Lai
Funding Agency and Grant Number
Corresponding Author	Yu-Jang Su, MD, Assistant Professor, Director, Doctor, Teacher, Department of Emergency Medicine, MacKay Memorial Hospital, No. 92, Sec 2, North Chung Shan Rd, Taipei City 10449, Taiwan. yjsu.5885@mmh.org.tw
Key Words	COVID-19; Fatty liver; Liver cirrhosis; Hepatitis; Hypoalbuminemia; Hepatic injury
Core Tip	The main cause of mortality in coronavirus disease 2019 (COVID-19) infection is the respiratory complication but liver is one of the most affected organs besides the respiratory system. The incidence of liver injury after COVID-19 infection ranged from 15%-53%. The COVID-19 infected patients with liver injury may have higher liver enzyme levels, lower monocyte count and longer prothrombin time. The risk of afterward sequela including transferring to intensive care unit, needing mechanical ventilator support, and acute kidney injury is higher than that may happen to COVID-19 patients without abnormal liver function tests. Higher mortality rate and longer length of stay are both observed.
Publish Date	2021-09-16 08:48
Citation	Su YJ, Chang CW, Chen MJ, Lai YC. Impact of COVID-19 on liver. World J Clin Cases 2021; 9(27): 7998-8007
URL	https://www.wjgnet.com/2307-8960/full/v9/i27/7998.htm
DOI	https://dx.doi.org/10.12998/wjcc.v9.i27.7998

Full Article (PDF)	WJCC-9-7998.pdf
Full Article (Word)	WJCC-9-7998.docx
Manuscript File	65277-Review-FilipodiaCL.docx
Answering Reviewers	65277-Answering reviewers.pdf
Audio Core Tip	65277-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	65277-Conflict-of-interest statement.pdf
Copyright License Agreement	65277-Copyright license agreement.pdf
Peer-review Report	65277-Peer-review(s).pdf
Scientific Misconduct Check	65277-Scientific misconduct check.pdf
Scientific Editor Work List	65277-Scientific editor work list.pdf